Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

1.1.	Product identifier					
	Trade name:	NATUI	RAL oil Cl	BD+CBDA 5 % in MCT oil		
	Main component:	Cannal	bis sativa	extract, MCT oil		
	Constituent name:			ethyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl -1,3-diol Cannabidiol, CBD		
	Chemical name:	1				
1.2.	Relevant identified us	es of the s	ubstance	e or mixture and uses advised against		
	Uses:			Industrial use; Intermediate		
	Uses advised against:			Bulk product		
	Reason why uses adv	sed agains	st:	None		
1.3.	Details of the supplier	of the saf	ety data	sheet		
	Supplier:		CBD Oi	il Europe		
	Address:		Voltawe	eg 11D, 4382 NG Vlissingen, the Netherlan		
	Telephone number:		+31 (0)	+31 (0) 64 0690002		
	e-mail of competent person:		info@cb	info@cbdoileurope.com		
	Production:		Croatia			
	Brand:		NATURAL oil			
1.4.	Emergency telephone number					
	National Protection and Rescue Directorate:			(EU) 112		
	Medical information:			SZT (CRO) +385 98 405 636		
	Other information:					
SECTI	ON 2. Hazards ide	ntificati	on			
2.1.	Classification of the s	ubstance c	r mixture	е		
2.1.1.	Classification according	ng to Regu	lation (EC	C) No 1272/2008 (CLP)		
	Hazard pictograms					
	GHS08		14/-	arning.		
2.1.2.	Signal word:  Additional information	2	vval	arning		
1.1./.						

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	Product ide		en Ca	[(1R,6R)-3-methyl-6-(prop- -1-yl]-5-pentylbenzene-1, nnabidiol, CBD AS:13956-29-1			
***************************************	Cosmetic Ir	ase (EU)	Ca	nnabidiol, CBD			
	CAS No. of the mixture:				ot assigned		
	EC No. of t	he mixture:		No	ot assigned		
	HS code of	the mixture:		13	302 19 (Vegetable saps and	extracts)	
	Hazard stat	tement:					
			H361		spected of damaging fertil	ity or the unborn	
	Precaution	ary statement:					
			P201	Ol	otain special instructions be	efore use.	
			P202		o not handle until all safety en read and understood	precautions have	
			P233	Κe	eep container tightly closed		
			P264	W	ash skin thoroughly after h	andling	
			P273	Α١	Avoid release to the environment		
			P280	Wear protective gloves/ eye protection /face protection			
			P370	In case of fire, use chemical foam, carbon dioxide			
2.3.	Other haza						
		e does not meet of Regulation (EG			BT or vPvB substances in ad [REACH].	ccordance with	
SECT	ION 3. Con	nposition/inf	ormation o	n i	ngredients		
	No./EC No. ex number	REACH Registration No	Conc. % content (or range)		Identification name	Classification according to Regulation (EC) No 1272/2008 (CLP)	
	None	None	5,00-6,67		Cannabis sativa extract - Natural	Not classified	
CAS: 73398-61-5/ 65381-09-1 EC: 277-452-2/ 265-724-3		93,33-96,0	0	MCT oil	Not classified		
	1011 1 =:						
		t aid measur					
4.1.	Descriptio	n of first aid mea			- alkla mushlam - C		
	General no	otes:		nges	ealth problems after produ stion) consult a medical d et.	· ·	

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	Following inhalation:	If symptoms of overexposure are experienced, move to fresh air. Rinse mouth and throat with plenty of water. Provide medical treatment if irritation, dyspnoea/shortness of breath or other symptoms should persist.				
	Following skin contact:	In case of exposure of clothes to product, remove contaminated clothes. Wash affected area with soap and water. If irritation or rash develops, seek medical attention.				
	Following eye contact:	t: Rinse eyes with water. If irritation persists, seek medica				
	Following ingestion:	Rinse mouth and throat with plenty of water. Drink plenty of water. If person feels unwell seek medical advice immediately and provide this Safety Data Sheet.  In case larger amounts of product vapours should have produced protect yourself with a particle-filtering face mask. Take off contaminated clothes after first aid and wash with plenty of water and liquid soap.				
	Self-protection of the first aider					
4.2.	Most important symptoms	and effects, both acute and delayed				
	Following inhalation:	Cough, shortness of breath.				
	Following skin contact:	On long-term exposition there may be redness, itching, rash.				
	Following eye contact:	There may be redness, discomfort, watering.				
	Following ingestion:	Large amounts could cause nausea, vomiting, and irritation of the throat.				
4.3.	Indication of any immediat	te medical attention and special treatment needed				
	prevent extended absorpti person should refrain from	abidiol contained is lipophilic and nearly not soluble in water. To fon of CBD in the digestive tract after oral uptake, the affected eating any fats or oils for at least 24 hours after ingestion.				
	Quantities of up to 1500 mg of CBD per day are well tolerated by adults.  Acute toxicity is so low that it needs not to be classified accordingly.					
		, this should be symptomatic.				
SECT	ION 5. Firefighting mea					
5.1.		isui es				
5.1.	Suitable extinguishing media:	Small fire: Use fire extinguishing methods suitable to surrounding conditions CO <sub>2</sub> , powder, or foam.  Large fire: Use water spray or alcohol resistant foam.  Treat as for vegetable oils.				
	Unsuitable extinguishing media:	Water with full jet.				
5.2.	Special hazards arising from	m the substance or mixture				
	Hazardous combustion products:	Smoke is produced in a fire, with potential production of carbon monoxide and carbon dioxide (immediately toxic gases). Inhalation of hazardous degradation products (such as small soot particles from pyrolysis) may cause serious health damage (fume poisoning).				

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

5.3.	Advice for firefighters					
		apparatus for firefighting and full protective gear if necessary.				
5.4.	Additional information					
	No data available.					
SECTI	ON 6. Accidental release r	neasures				
6.1.	Personal precautions, protectiv	e equipment and emergency procedures				
6.1.1.	For non-emergency personnel					
	Protective equipment:	For personal protection see SECTION 8				
	Accident prevention methods:	No special measures, spill area may be slippery.				
	Emergency procedures:	Avoid inhaling vapours of the melt and provide adequate ventilation (e.g. local exhaust ventilation).				
6.2.	Environmental precautions					
	See SECTION 12 for additional Ecological Information.					
6.3.	Methods and material for containment and cleaning up					
	Keep in suitable, closed contair	ners for disposal				
6.3.1.	Bonding, covering of drains; capping procedures:	product should be covered with suitable inon-tiammable.				
6.3.2.	Cleaning up:	Collected material should be disposed of in accordance with locally valid regulations.  After removal of the spilled product use plenty of water and soap for emulsification.				
6.3.3.	Other information:	Upon escape of large amounts of product inform the Fire Department and the Environmental Department of the Municipal Authority.				
6.4.	Reference to other sections					
	See SECTION 13 for Disposal.					
SECTI	ON 7. Handling and storag	ge				
7.1.	Precautions for safe handling					
7.1.1.	Protective measures					
	Provide appropriate exhaust ve	ntilation at storage and at the workplace.				
	Avoid contact with eyes, skir equipment. During work do not	n and clothing, do not inhale. Wear appropriate protective t eat, drink or smoke.				
	Normal measures for preventat	ive fire protection.				
7.1.2.	Advice on general occupational	hygiene				
	Handle in accordance with goo	d industrial, hygiene and safety practice.				
7.2.	Conditions for safe storage, inc	luding any incompatibilities				

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

8.2.2. 8.2.2.1. 8.2.2.2.	Personal protection equipmer  Eye and face protection:  Skin and hand protection:	Wear standard safety glasses. In case of contact, wear suitable gloves. Change gloves in accordance with manufacturer's recommendations. If gloves are damaged during use, remove immediately and wash		
Avoid inhaling vapours of the ventilation).		melt and provide adequate ventilation (e.g. local exhaust		
8.2.1.	Appropriate engineering cont			
8.2.	Exposure controls			
8.1.2.	DNEL/PNEC-values:	There are no established values for the products with Cannabidiol (CBD).  A No Observed Effect Level (NOEL) for Cannabidiol could be derived as ≥ 0.32 mg CBD oral / kg body mass from a human preclinical study		
8.1.1.	Occupational exposure limits:	There are no established occupational exposure limits for the mixture or the main constituent Cannabidiol.		
8.1.	Control parameters			
SECTIO	DN 8. Exposure controls/po			
	Recommendations:	Use in accordance with good manufacturing and industrial hygiene practices.		
7.3.	Specific end use(s)			
	Further information on storage conditions:	Keep away from heat/sparks/open flames/ hot surfaces – no smoking.  Avoid contact with strong bases (alkaline substances) and with strong acids.		
	Advices for storage equipment:	None		
		end products. To avoid migration of undesired substances from the (plastics) packaging into the mixture, food compatible packaging material should be chosen.		
	Packaging materials:	Containers made of glass, high density polyethylene (HDPE), polypropylene (PP), polyamide (PA), polytetrafluoroethylene (PTFE), ceramics, stainless steel, or aluminium with wide opening and tight seals. Use compatible packaging materials throughout for the uses, also fulfils the requirements for packaging of cosmetic		
	Technical measures and storage conditions:	Keep in original container tightly closed in dry and well-ventilated place. Recommended storage temperature not exceeding 30 °C.  Protect the mixture against direct sun light and heat.		

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

8.2.2.3.	Body protection:		The type of protective equipment must be selected according to the concentration and amount of the substance at the specific workplace.			
8.2.2.3. Respiratory protection:		mixture with efficient local exhau	Respiratory protection not required for handling of the mixture with efficient local exhaust ventilation. In a poorly ventilated environment wear respiratory mask for handling of the melt			
8.2.2.4.	Thermal hazards:	None				
8.2.3.	Environmental exposure	e controls				
	Control and change filter regular basis and provide waste disposal contracted					
	ON 9. Physical and che					
9.1.	• • • • • • • • • • • • • • • • • • • •	cal and chemical properties	D			
	Parameter	Value	Remark			
	Appearance/form:	Thick, viscous liquid				
Colour: Odour:		Dark yellow/ light brown liquid Flower odour / nutty, bitter taste				
	pH:	No data available				
	Melting point / freezing point;	No data available				
	Initial boiling point and boiling range:	Will degrade > 100 °C	experimental			
	Flash point:	> 200 °C	experimental			
	Evaporation rate:	No data available				
	Flammability (solid, gas):	No data available				
	Upper/lower flammability or explosive limits:	No data available				
	Vapour pressure:	< 0,1 mbar at 150 °C	experimental			
	Vapour density:	No data available				
	Relative density	< 0.95 based on oil	experimental			
	Bulk density:	No data available				
	Solubility(ies):	< 10 mg/l based on oil	estimated			
	Partition coefficient: n- octanol/water (log Kow):	No data available				
	Auto-ignition temperature:	No data available				

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	Decompo temperat		> 200°C		estimated		
	Viscosity	•	at 20 °C, 25	5 – 33 mPa s,	estimated		
	Explosive	properties:	Not classifi	ed as explosive			
	Oxidising	properties:	Not classifi	ed as oxidising			
9.2.	Other inf	ormation					
	Practicall	y insoluble in wat	er, soluble in	Ethanol, Methanol, vege	etable fats.		
SECTI	ON 10.: 9	Stability and r	eactivity				
10.1.	Reactivity			Cannabidiol (CBD) is	lia and the presence of air, oxidized to a quinone. With to give a complex mixture of		
10.2.	Chemical	stability		Stable under recomme	nded storage conditions.		
10.3.	Possibilit	Possibility of hazardous reactions		Hazardous polymerisation will not occur. Avoid contact with incompatible materials (see SECTION 10.5).			
10.4.	Condition	ns to avoid		Light, heat, moisture.			
10.5.	Incompat	tible materials		Strong oxidizing agents.			
				Strong reducing agents.			
				Strong base, strong aci	d.		
10.6.	Hazardou	us decomposition	products	None known.			
	•						
SECTI	ON 11. T	oxicological i	nformatio	n			
11.1.	Informati	on on toxicologic	al effects				
	Studies in animals indicate that a large portion of the administered CBD is excreted intact as its glucuronide. Due to extensive Phase I metabolism, the pharmacokinetics of CBD complex, and the bioavailability of oral CBD is low across species.  The most abundant metabolites are hydroxylated 7-COOH-derivatives of CBD that a excreted either intact or as glucuronide conjugates.						
11.2.	Acute to	kicity					
	There are	e no data available	e on acute or	al toxicity for this mixtur	e.		
	Data on acute oral toxicity for main constituent Cannabidiol (animal test):						
	Data Oil a	acute of all toxicity	Tor main cor	istituent Cannabiuloi (an	illiai testj.		
	Study ID Species Use do						

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

GWTX150 3 BioA		CD1 Mice/12	0-300 mg/kg/day	13-week	The NOAEL was 400 mg/kg/day for male (Cmax AUC value of 6420 ng/mL and 37800 ng h/mL) and 550 mg/kg/day for female (Cmax AUC value of 8440 ng/mL and 41200 ng h/mL).			
	X150 lioA	Wistar Rat/10	0-150 mg/kg/day	26-week + 4 weeks recovery	The NOAEL of 150 mg/kg/day for male (Cmax AUC value of 6160 ng/mL and 60000 ng /mL) and for female (Cmax AUC value of 7530 ng/mL and 67500 ng h/mL).			
	X150 lioA	Beagle dogs/4- 6	0-100 mg/kg/day	39-week+ 4 weeks recovery	The NOAEL of 100 mg/kg/day for male (Cmax AUC value 20500 ng /mL) and for female (Cmax AUC value of 22400 ng h/mL).			
	EMA, Epi	dyolex, EMEA/H/C/0	004675/0000, 20	19.				
	8							
11.2.1.		ent/Classification						
44.0		ture does not meet	the criteria for a	acute toxicity.				
11.3.		and corrosion		!!!t				
	May give	e mild skin irritatior	i, but not classif	ied as irritant.				
11.3.1.	Assessm	ent/Classification						
	Classific	ation criteria are no	ot met.					
11.4.	Serious e	eye damage / irritat	tion					
		mildly irritant to the		assified as irritant.				
11.4.1.	Assessm	ent/Classification						
	Based or	n available data, the	e classification c	riteria are not met.				
11.5.	Respirat	ory or skin sensitisa	ation					
		-		on to the skin of so	me individuals.			
11.5.1.	Assessm	nent/Classification						
	Based on available data, the classification criteria are not met.							
11.6.	CMD off	iocts (carcinogonisis	tv: mutagonicity	roproductivo tovio	ity)			
11.0.				; reproductive toxic	ily)			
	Summary of evaluation of the CMR properties;  There is no data available on CMR effects of product.							

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	There is data available for a Cannabis sativa extract with a higher content in CBD (a biological drug substance containing 69% of Cannabidiol): with that substance four genotoxicity assays have been conducted: AMES test (bacterial mutation assay), mouse mammalian cell mutation assay (mouse lymphoma), the mouse micronucleus assay, and the unscheduled DNA synthesis assay, which all produced negative results. At the concentrations tested, there were no genotoxic effects.  (Product Monograph Sativex®, GW Pharma Ltd., Cambridge, UK, Control N: 149598, date
11.6.1.	of Revision: March 31, 2015).  Carcinogenicity
	There are no reports on carcinogenic effects of the product. A biological substance (Cannabis sativa extract) containing 69% of Cannabidiol was evaluated in a 2-year carcinogenicity study in rats ( <i>GW Study No JJG003</i> ) with 15 and 50 mg/kg/d. There was no indication of carcinogenic potential.
11.6.2.	Mutagenicity
	Cannabidiol was evaluated in a range of in vitro and in vivo standard genotoxicity assays.

### In vitro mutagenicity / genotoxicity of Cannabidiol:

Cell type / Organism	Genetic Endpoint	Result / Evaluation	Remark
Fischer rat embryo (RLV/1706) cells	Cell transformation, viral enhanced (CTR-)	negative	Genetox Record No: 3129
Mammalian polychromatic erythrocytes	Micronucleus test, chromosome aberrations (MNT+)	positive	Genetox Record No: 3129
Human lymphocytes	Sister chromatid exchange (SCE) in vivo (SCY+)	positive	Genetox Record No: 3129

### In vivo mutagenicity / genotoxicity of Cannabidiol:

Effect dose/- concen tration	Value	Cell type/ Organism	Genetic Endpoint	Result/ Evaluation	Remark		
n.a.	n.a.	Male mouse	Sperm morphology (SPI-)	negative	Genetox Record No: 3129		
	The genotoxic potential of CBD has been evaluated in a standard test battery of in vitro and in vivo assays according to ICH S2(R1). All tests concluded CBD to be negative for genotoxic potential.						
11.6.3.	Reproductive toxicity						
	There is no data available on reproductive toxicity effects of this mixture.						
	Animal data on the main constituent Cannabidiol (CBD): Adverse effects of Cannabidiol on sexual function and fertility:						

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

Study type/ Study ID	Species; number group	Route & dose	Dosing period	Major findings	NOAEL (mg/kg)		
Male fertility GWTX1456/GLP	Wistar rat /20	75-250 mg/kg/day	2 weeks prior to pairing up to review of female pregnancy data	No effects on male reproductive organ weights	250 mg/kg/day		
Female fertility GWTX1456/GLP	Wistar rat /20	75-250 mg/kg/day	2 weeks prior to pairing up to GD 6	No effect on female reproductive indices, female oestrus cycling or pregnancy parameters	250 mg/kg/day		
Embryo-foetal development GWTX1455/non GLP	Wistar/6 DRF study	150-300 mg/kg/day	GD6 to 17	300 mg/kg/day: One dead rat, weight loss of 32% of controls. Increased preimplantation loss at 300 mg/kg/day. No adverse effects at lower doses	F0:250 mg/kg/day F1:250 mg/kg/day		
Embryo-foetal development GWTX1454/GLP Bioanalysis & TK: non-GLP	Wistar /20	75-250 mg/kg/day	GD6 to 17	Complete litter loss of 2/20 dams at 250 mg/kg/day	F0:150 mg/kg/day F1:150 mg/kg/day		
Embryo-foetal development DRF GWTX1453/ Non-GLP	Rabbit/6	50-125 mg/kg/day	GD7 to 19	Body weight loss compared to controls	DRF study NA		
Embryo- foetal development DRF GWTX1452/ GLP	Rabbit /22	50-125 mg/kg/day	GD7 to 19	Unossified metacarpal, bulging eyes, and nonerupted incisors) were considered to be secondary to the reduced fatal weights at 125 mg/kg/day.	F0:80 mg/kg/day F1:80 mg/kg/day		
Pre & postnatal development GWTX1532/GLP	Rat/22	75-250 mg/kg/day	GD6 to LD21	F1 males: Small testes F1 female: Reduced fertility indices	F0:250 mg/kg/day F1:75 mg/kg/day		
EMA, Epidyolex, I	EMEA/H/C/0046	75/0000, 20	19.	•	J. J. 1		
٨٥٥٥٥	A						
No hun	Assessment / Classification  No human data on the effect of CBD on fertility are available. No effect on reproductive ability of male or female rats was noted with an oral dose of up to 150 mg/kg/day CBD						
11.6.4. Specific	target toxicity –	single expos	ure (STOT SE1 and	d 2)			
CBD in	CBD induces liver injury						

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	Liver toxicity has been systematically monitored and may occur. These toxicity appear to be due to a direct hepatocellular effect of CBD-OS or its metabolites.	
	Committee on toxicity of chemicals in food, consumer products and the environment TOX/2020/02	
11.6.5.	Narcotic effects	
	CBD is not listed in the Single Convention on Narcotic Drugs, UN, 1961, as amended. CBD does not exert narcotic effects.	
	Assessment / Classification	
	The product does not have narcotic effects.	
11.6.6.	Aspiration hazard	
	Practical experience / human evidence: No data available	
	Assessment / Classification	
	Based on available data, the classification criteria are not met.	
11.2.	Practical experiences	
	Classification observations: No information available	
	Other observations:	
11.3.	General notes	
SECTION	ON 12. Ecological information	
12.1.	Toxicity	
12.1.	Aquatic toxicity	
	There is no experimental data on short-term or long-term aquatic toxicity of the mixture.	
	The main constituent Cannabidiol is nearly insoluble in water, this also applies to the glycerides (fats) present in the mixture. Therefore, accumulation by dissolution in surface waters is not probable.	
	Assessment / Classification:	
	No classification no data available	
12.2.	Persistence and degradability	

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	The product is composed of naturally occurring plant oils and is expected to be ultimately biodegradable.
12.3.	Bio accumulative potential
	There is no experimental data on bioaccumulative potential.
12.4.	Mobility in soil
	There are no experimental data on mobility in soil.
12.5.	Results of PBT and vPvB assessment
	Not required (for Chemical Safety Report only). This product does not meet the PBT/vPvB criteria of REACH, Annex XIII.
12.6.	Other adverse effects
	No data available

SECTI	ON 13. Disposal consider	ations	
13.1.	Waste treatment methods		
	Recovery and recycling are negulations.	ot possible. Incinerate or dispose of in accordance with local	
13.1.1.	Product/Packaging disposal		
	Dispose of packaging mater regulations.	rial as low-hazard packaging waste within scope of local	
13.1.2.	Other disposal recommendations		
	Do not empty unused product into drainage systems.		
	The product must not be disposed of with municipal waste.		
	Empty containers must be used at waste incinerators (plastic) to produce energy or deposited in a dump with appropriate classification.		
	Perfectly cleaned containers may be submitted for recycling.		
SECTI	ON 14. Transport informa	ation	
	Transporting/shipment		
14.1	UN number:		
	AND	None	
	ADR/RID	None	

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

	ICAO-TI/I	ATA-DGR	None		
	IMDG		None		
14.2	UN proper shipping name:				
	AND		Not dangerous goods		
	ADR/RID		Not dangerous goods		
***************************************	ICAO-TI/I	ATA-DGR	Not dangerous goods		
	IMDG		Not dangerous goods		
14.3	Transport hazard class(es):				
	AND		None		
***************************************	ADR/RID		None		
	ICAO-TI/I	ATA-DGR	None		
	IMDG		None		
	:		·		
14.4	Packing group:				
	AND		None		
	ADR/RID		None		
	ICAO-TI/I	ATA-DGR	None		
	IMDG		None		
14.5	Environmental hazards:				
	AND		None		
	ADR/RID		None		
	ICAO-TI/I	ATA-DGR	None		
	IMDG		None		
14.6	Special precautions for user:				
	Not dangerous goods in the meaning of transport regulation				
Further	information:	Store, cooled, at dry	and dark place.		
		Protect from direct	light and heat.		
		Keep out of reach o	of young children.		
			be transported in well closed containers or drums in		
SECTI	ON 15. Reg	gulatory informati	on		

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

15.1.	Safety, health, and environmental regulations/legislation specific for the substance or mixture				
	Authorisations: Not required for professional use.				
	Restrictions on use: None under professional use				
		F I I I I I I I I I I I I I I I I I I I			
	Restrictions of occu	upation: None			
15.2.	Chemical safety assessment				
	A Chemical Safety Assessment under the EU REACH Regulation is not required for this product.				
	ON 16. Other inf	ormation			
16.1	Indication of changes:				
	This safety data sh	eet is the original version 2.0, dated 01. April, 2021.			
16.2	Abbreviations and acronyms				
	ADR	European Agreement concerning the International Carriage of Dangerous Goods by Road			
	CAS	Chemical Abstracts Service			
	CLP	Classification, Labelling, Packaging			
	DNEL	Derived No Effect Level			
	EC	European Community			
	EU	European Union			
	IATA-DGR	International Air Transport Association - Dangerous Goods Regulations			
	ICAO-TI	International Civil Aviation Organization - Technical Instructions			
	IMDG	Code International Maritime Code for Dangerous Goods			
	LC	Lethal concentration			
	LD	Lethal dose			
	log KOW	Octanol-water partition coefficient			
	NOAEL No	Observed Adverse Effect Level			
	PBT	Persistent, Bioaccumulative, and Toxic			
	PNEC	Predicted No Effect Concentration			
	REACH	Registration, Evaluation, and Authorisation of Chemicals			
	vPvB	very Persistent and very Bioaccumulative			
	STOT	Specific Target Organ Toxicity (SE = Single Exposure, RE = Repeated Exposure)			

Product name: 5% Natural CBD+CBDA in MCT

Product code: CBD-OIL-5-NAT-MCT

UVCB	Substances of unknown or variable composition, complex reaction products or biological
VOC	Volatile Organic Compounds

#### ANNEX: Exposure scenario resulting to Chemical safety assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information, and belief at the date of its publication. The information given is designed as a guidance for safe handling, use, processing, storage, transportation, disposal, and release and is not to be considered a warranty or quality specification. The information in this document are applicable to the product regarding appropriate safety precautions. It does not represent any guarantee of properties of the product.

This information must be made available to those who may encounter the material or are responsible for the use of the material. This Safety Data Sheet is prepared in accordance with formatting described in the REACH Regulation (EC) No 1907/2006 and described in CLP Regulation (EC) No 1272/2008.

#### \*Further information:

Copyright 2021. License granted to make unlimited paper copies for internal use only.

CBD Oil Europe and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.